TrialSignal transduction and targeted therapy2026

Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.

Xiaodong Mo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.